CTOs on the Move

CIC Health

www.cic-health.com

 
CIC Health provides COVID-19 testing services to organizations and individuals. We simplify testing by integrating CLIA-certified laboratories, physician oversight, result reporting, and billing software. Whether a one-time test or routine testing for a business, school, care facility, or consumers, our services are accessible, fast, and easy.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Vinay Gidwaney
Head of Technology Profile

Similar Companies

Phoenix Care Systems

Phoenix Care Systems, Inc. is the parent company of Willowglen Academy, Inc., Bell Therapy, Inc. and Phoenix Pharmacy, Inc. Willowglen Academy has been a leader in providing community based treatment services to autistic and mentally ill children for nearly 30 years. Bell Therapy, a pioneer in the national movement to de-institutionalize mentally ill adults has been providing innovative treatment services that promote independence, dignity, and diversity, while enhancing the quality of life since 1972.

Westview Acres Care Ctr

Westview Acres Care Ctr is a Leon, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Axminster Medical Group

During the past 40 years, AXMINSTER Medical Group has earned the reputation as being a provider of distinctive care and service. The physicians and nurses at AXMINSTER Medical Group believe in a team approach to offering patient care. They work

Alzheirmer's Association

Alzheirmer's Association is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xenon Pharmateuticals

Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.